Itonic Holdings Ltd. (NASDAQ:ITOC) Short Interest Update

Itonic Holdings Ltd. (NASDAQ:ITOC) was the target of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 62,815 shares, a decline of 40.4% from the August 31st total of 105,460 shares. Currently, 0.4% of the company’s shares are short sold. Based on an average daily trading volume, of 117,111 shares, the short-interest ratio is currently 0.5 days.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Itonic from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, September 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Itonic Stock Performance

Itonic stock opened at $0.28 on Friday. Itonic has a 52-week low of $0.22 and a 52-week high of $1.15. The stock’s 50 day moving average price is $0.29 and its two-hundred day moving average price is $0.31.

Itonic (NASDAQ:ITOC) last announced its quarterly earnings data on Wednesday, September 30th. The company reported ($0.05) earnings per share for the quarter. The firm had revenue of $0.05 million for the quarter.

About Itonic

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.